Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
341. |
ECCT/24/09/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Teresa Kinyari Site(s) in Kenya 1. University of Nairobi Clinical Research Centre (Nairobi City county) 2. KEMRI-Mtwapa Clinical Annex (Kilifi county) 3. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 4. Clinical Research Health Network (CREA-N) (Machakos county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
View |
342. |
ECCT/21/02/03 | VAC078 A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria. |
Principal Investigator(s) 1. Mainga Patience Mayeso Hamaluba 2. Jean Bosco Ouedraogo 3. Halidou Tinto 4. Alassane Dicko 5. Ally Olotu Site(s) in Kenya KEMRI Wellcome Trust Research Programme |
View |
343. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
View |
344. |
ECCT/24/11/01 | Sparkle A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Site 1401:Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402:Ahero Clinical trials Unit (Kisumu county) 3. Site 1403:International Cancer institute (Uasin Gishu county) 4. Site 1404:Kondele Childrens Hospital (Kisumu county) 5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county) 6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county) |
View |
345. |
ECCT/25/03/05 | Sparkle Study -Site 1402 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 1401: Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402: Ahero Clinical trials Unit (Kisumu county) 3. Site 1403: International Cancer Institute (Uasin Gishu county) 4. Site 1404: Kondele Childrens Hospital (Kisumu county) 5. Site 1405: KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Site 1406: Gertrude’s Children’s Hospital. (Nairobi City county) |
View |